Salarius Pharmaceuticals Appoints Daniela Santiesteban, Ph.D., to Director of Targeted Protein Degradation Program
February 03, 2022 07:30 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals to Participate in Annual Benchmark Company Discovery One-on-One Conference
November 29, 2021 08:01 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
November 04, 2021 16:05 ET
|
Salarius Pharmaceuticals, Inc.
Cash and Cash Equivalents of $31.9 Million Sufficient to Fund Completion of Ongoing Clinical Trials for Lead Drug Candidate Seclidemstat Added Five New Clinical Sites to Sarcoma Trial; 13 Active...
Salarius Pharmaceuticals to Report Third Quarter 2021 Financial Results and Highlight Recent Company Progress
October 26, 2021 08:01 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals and Nationwide Children’s Hospital Disclose Research Findings from Presentation at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 09:05 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric...
Salarius Pharmaceuticals Receives $2.7 Million in Payment from the Cancer Prevention and Research Institute of Texas
September 28, 2021 07:01 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Sept. 28, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals to Present at the Virtual Benzinga Healthcare Small Cap Conference
September 27, 2021 08:03 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals to Present at the Virtual Diamond Equity Research Emerging Growth Invitational
August 12, 2021 14:00 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...
Salarius Pharmaceuticals to Report Second Quarter 2021 Financial Results
July 29, 2021 07:33 ET
|
Salarius Pharmaceuticals, Inc.
HOUSTON, July 29, 2021 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas,...